Home
Resources
Diseases
Compendium
Training
Evaluation
The Tool
The Tutorial
The Dashboard
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Selected
Pneumococcal disease
Type of publications
NITAG documentation (91)
Reports (1)
SAGE documentation (12)
Scientific publications (1)
Systematic reviews (SYSVAC) (179)
Regions
Africa (12)
Americas (52)
Eastern Mediterranean (1)
Europe (42)
South-East Asia (5)
Western Pacific (16)
Diseases
Pneumococcal disease (284)
Chikungunya (9)
Cholera (35)
COVID-19 (1533)
Cytomegalovirus (1)
Dengue (40)
Diphtheria (80)
Ebola (16)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (68)
Hepatitis A (64)
Hepatitis B (159)
Hepatitis C (4)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (73)
HIV / AIDS (10)
Human papillomavirus (HPV) (501)
Influenza (595)
Japanese encephalitis (34)
Lyme disease, Borreliosis (1)
Malaria (29)
Measles (134)
Meningococcal disease (148)
Moraxella catarrhalis (1)
Mpox (55)
Mumps (46)
Pertussis (108)
Poliomyelitis (86)
Q fever (1)
Rabies (30)
Rotavirus (118)
RSV (Respiratory syncytial virus) (56)
Rubella (65)
Salmonella (3)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (60)
Tick-borne encephalitis (12)
Tuberculosis (78)
Typhoid (25)
Varicella (74)
Yellow fever (42)
Zika (1)
Show more
Methodological quality (AMSTAR 2)
High (10)
Moderate (2)
Low (16)
Critically low (83)
Not applicable (68)
284 results found
2023
∙
ACIP
Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023
2023
∙
Haute Autorité de Santé
Vaccination strategy against pneumococcal infections - Place of pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) in adults
2023
Pneumococcal vaccination of children in the netherlands
2023
Pneumococcal vaccination of the elderly in the netherlands
2023
∙
NACI
Recommendations on the use of conjugate pneumococcal vaccine – 15 valent (PNEU-C-15) and 20 valent (PNEU-C-20) in adults: Economic evidence supplementary appendix
2023
∙
NACI
Public health level recommendations on the use of pneumococcal vaccines in adults, including the use of 15-valent and 20-valent conjugate vaccines
2023
∙
NACI
Interim guidance on the use of pneumococcal 15-valent conjugate vaccine (PNEU-C-15) in pediatric populations
2023
∙
Conseil Supérieur de la Santé (CSS)
Pneumococcal vaccination in children and adolescents in Belgium
2022
∙
Nor, S. F. S. Aminuddin, N. A. Ahmad, N. Hassan, M. R. Nawi, A. M. Ahmad, N. Pang, N. T. P. Omar, A. Madrim, M. F. Mokti, K. Ramdzan, A. R. Rahim, S. S. S. A. Jeffree, M. S.
A Systematic Review and Meta-Analysis of Mobile Phone Messaging Intervention on Vaccine Preventable Diseases
2022
∙
Mungall, B. A. Hoet, B. Nieto Guevara, J. Soumahoro, L.
A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register